Jade Biosciences, Inc. last reported quarterly results on Aug 10, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.76. It usually reports 5–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on last year's release for the same quarter on Nov 14, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 5–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-56
-73.5%
|
-0.76
+11.6%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-40
-5.8%
|
-0.57
+95.3%
|
|
Jan 5, 2026
5 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-32
-488.1%
|
-0.50
-162.6%
|
|
Nov 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-25
-54.7%
|
-0.48
+90.7%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-32
-29.7%
|
-0.86
+0.0%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-38
-64.6%
|
-12.10
-1357.8%
|
|
May 13, 2024
43 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Nov 13, 2023
44 days after quarter end
|
—
ended Sep 30, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1798749
- Former names
- Aerovate Therapeutics, Inc. (until Apr 30, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.